Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept Cerebral Perfusion and Oxygenation in NTDT Beta-Thalassemia
2023-504908-28-01Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of luspatercept in beta thalassemia, sponsored by Amsterdam University Medical Center. Planned start Nov 2023; status: authorised.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2023-504908-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504908-28-01.